Company intelligence / Profile preview
Aura Biosciences, Inc.
Boston, Massachusetts, United Statesaurabiosciences.com ↗
- Ownership
- Public · AURA
- Employees
- ~109
- Development stage
- Phase 2
01
Overview
Aura Biosciences recently presented positive Phase 1 trial results for its lead candidate bel-sar in non-muscle invasive bladder cancer, showing clinical complete responses. The company is actively enrolling patients in its Phase 3 CoMpass trial for early-stage choroidal melanoma and has initiated a Phase 2 trial for metastases to the choroid[6].
- Therapeutic areas
- Oncology
- Modalities
- Virus-like drug conjugates (VDCs)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Financials
- Market cap
- $657.5M
- Total revenue
- $0
- Enterprise value
- $350.2M
Beyond the preview
Go deeper on Aura Biosciences, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aura Biosciences, Inc..